^
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
sacituzumab govitecan-hziy Sensitive: A1 - Approval
Gilead Press Release - 4 days
|
sacituzumab govitecan-hziy Sensitive: A1 - Approval
Gilead Press Release - 4 days
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
lapatinib Sensitive: A2 - Guideline
Nature - 4 days
|
lapatinib Sensitive: A2 - Guideline
Nature - 4 days
|
HER-2 amplification + HER-2 L755S
|
HER2 Positive Breast Cancer
|
HER-2 amplification + HER-2 L755S
|
HER2 Positive Breast Cancer
|
pyrotinib Sensitive: C4 – Case Studies
Front Oncol - 5 days
|
pyrotinib Sensitive: C4 – Case Studies
Front Oncol - 5 days
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
exemestane Sensitive: A2 - Guideline
SABCS 2021 - 1 week
|
exemestane Sensitive: A2 - Guideline
SABCS 2021 - 1 week
|
ESR1 mutation + HR positive
|
HER2 Negative Breast Cancer
|
ESR1 mutation + HR positive
|
HER2 Negative Breast Cancer
|
palbociclib Sensitive: B - Late Trials
SABCS 2021 - 1 week
|
palbociclib Sensitive: B - Late Trials
SABCS 2021 - 1 week
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + tucatinib Sensitive: A1 - Approval
SABCS 2021 - 1 week
|
trastuzumab + tucatinib Sensitive: A1 - Approval
SABCS 2021 - 1 week
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
SABCS 2021 - 1 week
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
SABCS 2021 - 1 week
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
palbociclib Sensitive: A1 - Approval
JAMA Oncol - 1 week
|
palbociclib Sensitive: A1 - Approval
JAMA Oncol - 1 week
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
abemaciclib Sensitive: A1 - Approval
FDA - 1 week
|
abemaciclib Sensitive: A1 - Approval
FDA - 1 week
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
pyrotinib Sensitive: B - Late Trials
SABCS 2021 - 1 week
|
pyrotinib Sensitive: B - Late Trials
SABCS 2021 - 1 week
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
ribociclib + letrozole Sensitive: B - Late Trials
SABCS 2021 - 1 week
|
ribociclib + letrozole Sensitive: B - Late Trials
SABCS 2021 - 1 week
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
trastuzumab + MCLA-128 Sensitive: C3 – Early Trials
SABCS 2021 - 1 week
|
trastuzumab + MCLA-128 Sensitive: C3 – Early Trials
SABCS 2021 - 1 week
|
ASXL1 mutation
|
Estrogen Receptor Positive Breast Cancer
|
ASXL1 mutation
|
Estrogen Receptor Positive Breast Cancer
|
CDK6 inhibitor Sensitive: C3 – Early Trials
SABCS 2021 - 1 week
|
CDK6 inhibitor Sensitive: C3 – Early Trials
SABCS 2021 - 1 week
|
ASXL1 mutation
|
Estrogen Receptor Positive Breast Cancer
|
ASXL1 mutation
|
Estrogen Receptor Positive Breast Cancer
|
CDK4 inhibitor Sensitive: C3 – Early Trials
SABCS 2021 - 1 week
|
CDK4 inhibitor Sensitive: C3 – Early Trials
SABCS 2021 - 1 week
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
EC Sensitive: C4 – Case Studies
Front Endocrinol (Lausanne) - 1 week
|
EC Sensitive: C4 – Case Studies
Front Endocrinol (Lausanne) - 1 week
|
PIK3CA H1047R + PIK3CA D959N + ER E380Q
|
HER2 Negative Breast Cancer
|
PIK3CA H1047R + PIK3CA D959N + ER E380Q
|
HER2 Negative Breast Cancer
|
abemaciclib Resistant: C4 – Case Studies
Front Endocrinol (Lausanne) - 1 week
|
abemaciclib Resistant: C4 – Case Studies
Front Endocrinol (Lausanne) - 1 week
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER2 inhibitor Sensitive: A2 - Guideline
Breast - 2 weeks
|
HER2 inhibitor Sensitive: A2 - Guideline
Breast - 2 weeks
|
IGFBP7 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
IGFBP7 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
tamoxifen Sensitive: B - Late Trials
Carcinogenesis - 2 weeks
|
tamoxifen Sensitive: B - Late Trials
Carcinogenesis - 2 weeks
|
HR negative
|
HER2 Negative Breast Cancer
|
HR negative
|
HER2 Negative Breast Cancer
|
AMG479 Sensitive: C3 – Early Trials
Nature - 2 weeks
|
AMG479 Sensitive: C3 – Early Trials
Nature - 2 weeks
|
IGFBP5-L
|
HER2 Negative Breast Cancer
|
IGFBP5-L
|
HER2 Negative Breast Cancer
|
AMG479 Sensitive: C3 – Early Trials
Nature - 2 weeks
|
AMG479 Sensitive: C3 – Early Trials
Nature - 2 weeks
|
IRS1-L
|
HER2 Negative Breast Cancer
|
IRS1-L
|
HER2 Negative Breast Cancer
|
AMG479 Sensitive: C3 – Early Trials
Nature - 2 weeks
|
AMG479 Sensitive: C3 – Early Trials
Nature - 2 weeks
|
FGFR4 overexpression
|
Breast Cancer
|
FGFR4 overexpression
|
Breast Cancer
|
FGFR inhibitor Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
|
FGFR inhibitor Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
|
FGFR3 overexpression
|
Breast Cancer
|
FGFR3 overexpression
|
Breast Cancer
|
FGFR inhibitor Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
|
FGFR inhibitor Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
|
FGFR2 overexpression
|
Breast Cancer
|
FGFR2 overexpression
|
Breast Cancer
|
FGFR inhibitor Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
|
FGFR inhibitor Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
|
FGFR1 overexpression
|
Breast Cancer
|
FGFR1 overexpression
|
Breast Cancer
|
FGFR inhibitor Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
|
FGFR inhibitor Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: A1 - Approval
Cancer - 2 weeks
|
ado-trastuzumab emtansine Sensitive: A1 - Approval
Cancer - 2 weeks
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: A1 - Approval
Mol Oncol - 3 weeks
|
trastuzumab Sensitive: A1 - Approval
Mol Oncol - 3 weeks
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
Oncogene - 3 weeks
|
neratinib Sensitive: A1 - Approval
Oncogene - 3 weeks
|
MSI-H/dMMR
|
Breast Cancer
|
MSI-H/dMMR
|
Breast Cancer
|
pembrolizumab Sensitive: A2 - Guideline
Clin Nucl Med - 3 weeks
|
pembrolizumab Sensitive: A2 - Guideline
Clin Nucl Med - 3 weeks
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
eribulin mesylate Sensitive: C2 – Inclusion Criteria
SAGE Journals - 3 weeks
|
eribulin mesylate Sensitive: C2 – Inclusion Criteria
SAGE Journals - 3 weeks
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
Cancer - 2 weeks
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
Cancer - 2 weeks
|
CXXC5 overexpression
|
HER2 Positive Breast Cancer
|
CXXC5 overexpression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
Cancer - 2 weeks
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
Cancer - 2 weeks
|
PGR overexpression
|
HER2 Positive Breast Cancer
|
PGR overexpression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
Cancer - 2 weeks
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
Cancer - 2 weeks
|
GRB7 overexpression
|
HER2 Positive Breast Cancer
|
GRB7 overexpression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
Cancer - 2 weeks
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
Cancer - 2 weeks
|
BAG1 overexpression
|
HER2 Positive Breast Cancer
|
BAG1 overexpression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
Cancer - 2 weeks
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
Cancer - 2 weeks
|
RRM2 overexpression
|
HER2 Positive Breast Cancer
|
RRM2 overexpression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
Cancer - 2 weeks
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
Cancer - 2 weeks
|
ER overexpression
|
HER2 Positive Breast Cancer
|
ER overexpression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
Cancer - 2 weeks
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
Cancer - 2 weeks
|
SLC39A6 overexpression
|
HER2 Positive Breast Cancer
|
SLC39A6 overexpression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
Cancer - 2 weeks
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
Cancer - 2 weeks
|
TMEM45B overexpression
|
HER2 Positive Breast Cancer
|
TMEM45B overexpression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
Cancer - 2 weeks
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
Cancer - 2 weeks
|
MAPT overexpression
|
HER2 Positive Breast Cancer
|
MAPT overexpression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
Cancer - 2 weeks
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
Cancer - 2 weeks
|
FBXL20 overexpression
|
Breast Cancer
|
FBXL20 overexpression
|
Breast Cancer
|
SA033 Resistant: D – Preclinical
J Biol Chem - 3 weeks
|
SA033 Resistant: D – Preclinical
J Biol Chem - 3 weeks
|
MUC1 expression
|
HER2 Positive Breast Cancer
|
MUC1 expression
|
HER2 Positive Breast Cancer
|
MUC1 inhibitor Sensitive: D – Preclinical
Acta Biochim Biophys Sin (Shanghai) - 2 weeks
|
MUC1 inhibitor Sensitive: D – Preclinical
Acta Biochim Biophys Sin (Shanghai) - 2 weeks
|
FGFR2 amplification
|
Breast Cancer
|
FGFR2 amplification
|
Breast Cancer
|
TAS 120 Sensitive: C2 – Inclusion Criteria
Cancer Discov - 3 weeks
|
TAS 120 Sensitive: C2 – Inclusion Criteria
Cancer Discov - 3 weeks
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: A1 - Approval
|
trastuzumab + pertuzumab Sensitive: A1 - Approval
|
HER-2 amplification
|
Breast Cancer
|
HER-2 amplification
|
Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
margetuximab Sensitive: A1 - Approval
|
margetuximab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel + doxorubicin hydrochloride + cyclophosphamide oral Sensitive: A1 - Approval
|
docetaxel + doxorubicin hydrochloride + cyclophosphamide oral Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
TAC Sensitive: A1 - Approval
|
TAC Sensitive: A1 - Approval
|
HR positive
|
HER2 Positive Breast Cancer
|
HR positive
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
ribociclib Sensitive: A1 - Approval
|
ribociclib Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval
|
pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
alpelisib Sensitive: A1 - Approval
|
alpelisib Sensitive: A1 - Approval
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
ribociclib Sensitive: A1 - Approval
|
ribociclib Sensitive: A1 - Approval
|
ER negative
|
Breast Cancer
|
ER negative
|
Breast Cancer
|
toremifene Resistant: A1 - Approval
|
toremifene Resistant: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
toremifene Sensitive: A1 - Approval
|
toremifene Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
albumin-bound paclitaxel Sensitive: A1 - Approval
|
albumin-bound paclitaxel Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
lapatinib Sensitive: A1 - Approval
|
lapatinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
|
trastuzumab + lapatinib Sensitive: A1 - Approval
|
trastuzumab + lapatinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
lapatinib Sensitive: A1 - Approval
|
lapatinib Sensitive: A1 - Approval
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
everolimus Sensitive: A1 - Approval
|
everolimus Sensitive: A1 - Approval
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel + doxorubicin hydrochloride Sensitive: A1 - Approval
|
docetaxel + doxorubicin hydrochloride Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel Sensitive: A1 - Approval
|
docetaxel Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel + capecitabine Sensitive: A1 - Approval
|
docetaxel + capecitabine Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
capecitabine Sensitive: A1 - Approval
|
capecitabine Sensitive: A1 - Approval
|
HR positive
|
HER2 Positive Breast Cancer
|
HR positive
|
HER2 Positive Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
fulvestrant Sensitive: A1 - Approval
|
fulvestrant Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
eribulin mesylate Sensitive: A1 - Approval
|
eribulin mesylate Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
non-pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
non-pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab/hyaluronidase-oysk Sensitive: A1 - Approval
|
trastuzumab/hyaluronidase-oysk Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
exemestane Sensitive: A1 - Approval
|
exemestane Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
exemestane Sensitive: A1 - Approval
|
exemestane Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
letrozole Sensitive: A1 - Approval
|
letrozole Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
letrozole Sensitive: A1 - Approval
|
letrozole Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
anastrozole Sensitive: A1 - Approval
|
anastrozole Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
anastrozole Sensitive: A1 - Approval
|
anastrozole Sensitive: A1 - Approval
|
ER negative
|
Breast Cancer
|
ER negative
|
Breast Cancer
|
anastrozole Sensitive: A1 - Approval
|
anastrozole Sensitive: A1 - Approval
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
toremifene Sensitive: A1 - Approval
|
toremifene Sensitive: A1 - Approval
|
HER-2 amplification
|
Breast Cancer
|
HER-2 amplification
|
Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
ixabepilone Sensitive: A1 - Approval
|
ixabepilone Sensitive: A1 - Approval
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
fulvestrant Sensitive: A1 - Approval
|
fulvestrant Sensitive: A1 - Approval
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
fulvestrant Sensitive: A1 - Approval
|
fulvestrant Sensitive: A1 - Approval
|
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
leuprorelin depot Sensitive: A1 - Approval
|
leuprorelin depot Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab + docetaxel Sensitive: A1 - Approval
|
trastuzumab + docetaxel Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
TCHP Sensitive: A2 - Guideline
|
TCHP Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
ER positive
|
HER2 Positive Breast Cancer
|
ER positive
|
HER2 Positive Breast Cancer
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Breast Cancer
|
NTRK2 fusion
|
Breast Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
